Recombinant hepatitis E vaccine

Available from Drugdu Technology Co., Ltd

Product Information
Dosage Form:Injection
Route of Administration:Intramuscular Injection
Shelf Life:3 years
Storage:2℃-8℃
Qualification: Chinese GMP

Description
[Quality standard] Company Standard (YBS01402011)
[Suitable population] This product is suitable for susceptible population aged 16 and above. It is recommended for individuals exposed to high risk of hepatitis E virus infection, such as those engaged in animal husbandry and catering, students, officers and soldiers, women of childbearing age, travelers to endemic areas and so on.
[Specification] 30µg/0.5ml/dose
[Route of Administration] 3 doses of intramuscular injection following the 0, 1 months, 6 months schedule, that is the first dose on the first day, the second dose one month after the first injection,and the third dose six months after the first injection.
[Shelf life] 2-8℃ for 36 months
[Highlights]
•Launched in Oct. 2012, China
•The world's first vaccine against hepatitis E
•Up to 4.5 years, the long-term efficacy against clinical HE was 93.3% (78.6-97.9) and 86.8% (71.0-94.0) in per-protocol and intention-to-treat analysis, respectively.
•Complete phase I, II, III, IV Clinical Trial conducted in China

Rate and Review Drugdu Technology Co., Ltd

Rating: 0 - 0 reviews
Let users know what you would have wanted to know about this company.
Click on a star to rate this company
 
  Privacy Policy.
When writing a review, please adhere to the Review Guidelines.